Get the Stockscreener App
26.72
1.75%
0.46
After Hours:
26.72
Celldex Therapeutics Inc stock is traded at $26.72, with a volume of 461.41K.
It is up +1.75% in the last 24 hours and up +4.37% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
See More
Previous Close:
$26.26
Open:
$26.62
24h Volume:
461.41K
Relative Volume:
0.38
Market Cap:
$1.77B
Revenue:
$5.79M
Net Income/Loss:
$-199.61M
P/E Ratio:
-8.8771
EPS:
-3.01
Net Cash Flow:
$-188.48M
1W Performance:
-0.41%
1M Performance:
+4.37%
6M Performance:
+36.47%
1Y Performance:
-5.01%
1-Day Range:
$26.18
$26.77
1-Week Range:
$25.97
$28.59
52-Week Range:
$14.40
$29.38
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
26.72 | 1.74B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-13-25 | Initiated | Barclays | Underweight |
| Apr-28-25 | Initiated | Canaccord Genuity | Buy |
| Mar-20-25 | Initiated | Morgan Stanley | Overweight |
| Feb-13-25 | Initiated | UBS | Buy |
| Oct-07-24 | Initiated | Citigroup | Buy |
| Sep-30-24 | Initiated | Goldman | Neutral |
| Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
What momentum shifts mean for Celldex Therapeutics Inc.2025 Volatility Report & Weekly Chart Analysis and Guides - newser.com
Real time alert setup for Celldex Therapeutics Inc. performanceJuly 2025 Market Mood & Scalable Portfolio Growth Ideas - newser.com
Will Celldex Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Action & Verified Entry Point Detection - newser.com
What’s next for Celldex Therapeutics Inc. stock price2025 Biggest Moves & AI Forecast for Swing Trade Picks - newser.com
Why analysts remain bullish on Celldex Therapeutics Inc. stockMarket Weekly Review & Free High Accuracy Swing Entry Alerts - newser.com
Is Celldex Therapeutics Inc. stock a bargain at current levelsPortfolio Update Summary & Safe Capital Growth Tips - newser.com
Can Celldex Therapeutics Inc. stock reach $100 price targetJuly 2025 Market Mood & AI Driven Stock Price Forecasts - newser.com
Chart overlay techniques for tracking Celldex Therapeutics Inc.Weekly Investment Recap & Community Verified Trade Alerts - newser.com
Published on: 2025-10-25 11:53:34 - newser.com
How Celldex Therapeutics Inc. (TCE2) stock trades in high volatilityMarket Movers & Verified Technical Signals - newser.com
Is it too late to sell Celldex Therapeutics Inc.Weekly Market Summary & Weekly High Potential Stock Alerts - newser.com
Published on: 2025-10-25 02:57:01 - newser.com
Published on: 2025-10-24 02:30:04 - newser.com
Celldex Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Published on: 2025-10-23 07:06:05 - newser.com
Celldex Therapeutics (CLDX): Evaluating Valuation After Barclays' Underweight Rating and Industry Concerns - Yahoo Finance
Celldex Therapeutics Receives Bullish Analyst Coverage Amid Pipeline Developments - AD HOC NEWS
Will Celldex Therapeutics Inc. (TCE2) stock hit Wall Street targetsJobs Report & High Return Trade Guides - newser.com
Is Celldex Therapeutics Inc. reversing from oversold territoryMarket Growth Review & Weekly Market Pulse Alerts - newser.com
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):